Our clinic has participated in the international clinical trial named “A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3)”
The new drug, developed by Boehringer-Ingelheim, is a glutamate-based medication that is expected to revolutionize the limitations of existing treatments for schizophrenia. This compound is a glycine transporter inhibitor that is being developed for the treatment of schizophrenia but was discontinued for Alzheimer’s disease. Glycine transporters GlyT-1 and GlyT-2 located in presynaptic and astrocyte membranes take up glycine into the nerve terminal and adjacent glial cells, thus modulating glycine levels in the synaptic cleft. By blocking these receptors, BI 425809 is proposed to increase glycine levels and its ability to modulate NMDA receptor function.
The drug is aimed to improve the cognition and daily functioning of patients. Patient recruitment is scheduled for April.